Factor X deficiency is a haemorrhagic condition of variable severity. Over 50 families have been reported (1-4), transmission being normally incompletely autosomal recessive. The most severely affected patients often exhibit haemarthroses. Heterozygotes sometimes exhibit abnorrnal bleeding during surgery but in the absence of a haemostatic challenge, they are clinically asymptomatic. Cases of homozygous factor X deficiency ile frequently found to be associated with consanguinity. Factor X is the rymogen of factor Xa, a serine protease which occupies a pivotal position in the clotting process. It is activated either by the contact-activated (intrinsic) pathway or by the tissue factor (extrinsic) pathway. Factor Xa, in combination with factor V then activates prothrombin to form the effector ewnyme of the coagulation cascade. A continuous low-level generation of factor Xa occurs in the quiescent state and may provide the initial activator for coagulation after injury. Despite the availability of crystal stnrcture data, the regrons of factor X involved in factor V binding are only just beginning to be defined. One way of shedding light on structure-firnction relationships is through the study of naturally occurring variants. These are reviewed here together with a resum6 of the structure, function and molecular genetics of factor X. Physiology, Structure and Function Factor X synthesis occurs in the liver (5-7) and is vitarrin K-dependent; Warfarin, which antagonizes vitamin K action, causes a marked fall in the level of factor X activity and a moderate fall in factor X antigen (8). Factor X occurs in plasma [concentration-10 pE ml-t] as a two chain glycoprotein of Mr 59 kD (Fig. 1). The light chain (Mr 17kD) is cleaved from the heavy chain (Mr 42 kD) during or after secretion. Plasma levels ilre lower in women as compared to men and lower in premenopausal women as